CAC
TVRD

Certified Advisory Corp’s Tvardi Therapeutics TVRD Stock Holding History

Certified Advisory Corp’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17
Closed -$12K – 842
2019
Q1 		$12K Buy
17
+14
+467% +$8.38K 0.01% 532
2018
Q4 		$1K Hold
3
– – ﹤0.01% 723
2018
Q3 		$2K Hold
3
– – ﹤0.01% 726
2018
Q2 		$2K Hold
3
– – ﹤0.01% 716
2018
Q1 		$1K Buy
+3
New +$1.46K ﹤0.01% 719

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Certified Advisory Corp's TVRD Position: Q2 2019 in Review

Certified Advisory Corp sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 17 shares — an estimated $12K sold.

Certified Advisory Corp first reported a position in TVRD in Q1 2018 and held it in 5 quarters. The position peaked at $12K in Q1 2019. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

  • Certified Advisory Corp reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Certified Advisory Corp sold 17 Tvardi Therapeutics shares in Q2 2019, an estimated $12K.
  • Certified Advisory Corp first reported a position in Tvardi Therapeutics in Q1 2018 and held it in 5 quarters.
  • Certified Advisory Corp's Tvardi Therapeutics position peaked at $12K in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on Certified Advisory Corp's 13F filing for Q2 2019, filed 7 Aug 2019.